ENXTPA:BIMMedical Equipment
A Look At bioMérieux (ENXTPA:BIM) Valuation After New Sepsis Diagnostic Study Evidence
bioMérieux (ENXTPA:BIM) has put fresh data on the table, with a new Office of Health Economics study linking its fast ID/AST diagnostics to fewer sepsis cases and lower treatment costs across G7 health systems.
See our latest analysis for bioMérieux.
The new sepsis data lands at a time when bioMérieux’s €71.7 share price has a 1 day share price return of 5.05%, but a 30 day share price return of 23.44% decline and a 1 year total shareholder return of 39.10% decline, pointing to pressure that...